Please click here to obtain permission to reproduce this image.
Click on image to view larger version.
Figure 3 Benefits of upstream versus selective glycoprotein (GP) IIb/IIIa use by rates of percutaneous coronary intervention (PCI). CE = cost effectiveness.
